Effects of Tolperisone on Measures of Drowsiness and Cognitive Function
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Registration Number
- NCT04407377
- Lead Sponsor
- Neurana Pharmaceuticals, Inc.
- Brief Summary
A Randomized, 4-Period, Crossover Study to characterize the effects of tolperisone 200 mg and 400 mg (supratherapeutic dose) three times a day (TID) over 3 days of dosing on measures of simulated driving performance, cognitive function and drowsiness and compared to placebo and cyclobenzaprine (single-day, residual effect, multiple-day).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 39
Inclusion Criteria
- Ambulatory male or female, between 21 and 65 years of age, inclusive, for the entire duration of the study (from Screening through Day 3 of last treatment period).
- Body mass index (BMI) range between 18.5 and 30.0 kg/m2, inclusive.
- Subject must possess a valid driver's license and be an active driver and have driven a minimum of 10,000 miles (about 16,000 km) per year for the previous 3 years.
- Subject must demonstrate simulator sickness questionnaire scores that are not indicative of simulator sickness as defined in the driving simulation operations manual.
- Subject must have a regular sleep pattern, not be engaged in shift-work, and in general, have at least 7 hours of sleep each night.
Exclusion Criteria
- History of sleep disorders, including insomnia, sleep apnea, Restless Legs Syndrome (RLS), or narcolepsy, night-shift workers, routine daytime napping or oversleeping on weekends days (off work) or a score higher than 10 on the Epworth Sleepiness Scale (ESS) at Screening.
- A history of difficulty in falling asleep or staying asleep in the previous 3 months that is considered clinically significant by the Investigator.
- Subject has traveled across 2 or more time zones (trans meridian travel) in the last 2 weeks prior to randomization or is expected to travel across 2 or more time zones during the study.
- Subject has any physical condition (e.g., severe vision issues, hand use limitations) that would prevent the subject from performing the cognitive or drowsiness assessments.
- Subject has a presence or history of any medically diagnosed, clinically significant psychiatric disorder, including depression, anxiety, insomnia, schizophrenia, or bipolar disorder.
- Consumes more than 3 cups of coffee per day.
- Female subjects who are pregnant or lactating.
- Any clinically significant medical abnormality, any clinically significant chronic disease, or any clinically significant finding on physical examination.
- Subject with a genotype status of poor-, ultrarapid-, or indeterminate- metabolizers of cytochrome CYP2D6.
- Subject is unable to remain in the research unit for each of the treatment periods.
- Subject has visual or auditory impairment which in the opinion of the Investigator would interfere with study related procedures or study conduct.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description Tolperisone 200 mg Tolperisone Hydrochloride Study Drug, Tolperisone 200mg TID Tolperisone 400 mg Tolperisone Hydrochloride Study Drug, Tolperisone 400mg TID Cyclobenzaprine Cyclobenzaprine Hydrochloride 10 MG Active Comparator, Cyclobenzaprine 10mg TID Placebo Placebo Placebo, TID
- Primary Outcome Measures
Name Time Method Driving Performance Day 1 Standard Deviation of Lateral Position, measured by simulated driving performance using Cognitive Research Corporation Driving Simulator-MiniSim (CRCDS-MiniSim), of tolperisone compared to placebo
- Secondary Outcome Measures
Name Time Method Rapid Visual Information Processing Day 1 Measure of Cognitive Function
Reaction Time Day 1 Measure of Cognitive Function
CogScreen Symbol Digit Coding Test Day 1 Measure of Cognitive Function
Epworth Sleepiness Scale Day 3 Measure of Drowsiness
Karolinska Sleepiness Scale Day 1 Measure of Drowsiness
Trial Locations
- Locations (2)
CNS Trial
🇺🇸Long Beach, California, United States
Hassman Research Institute
🇺🇸Berlin, New Jersey, United States